Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Addiction Therapies Inc.

Latest From Addiction Therapies Inc.

Addiction Therapies Inc.

Positing substance addiction as a memory disease, Addiction Therapies Inc. seeks to address both its chemical and behavioral components. Initially targeting nicotine, alcohol and cocaine addiction, ATI will combine novel therapeutics drugs with proprietary dosing strategies in a platform designed to actively engage addicts in their own recovery.

Start-Up Previews (2/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Small Size=Big Potential , features profiles of C Sixty Inc., engeneOS Inc., Nanospectra Biosciences Inc. and Oxonica Ltd., Plus these Selected Start-Ups across Health Care: Addiction Therapies Inc., ImpactRx Inc., Ingenium Pharmaceuticals AG and Insulet Corp.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Addiction Therapies Inc.
  • Senior Management
  • David C Dlesk, CEO
    Barbara S Fox, PhD, Pres. & CSO
  • Contact Info
  • Addiction Therapies Inc.
    Phone: (508) 647-5622
    25 Main St.
    Ste. 3
    Wayland, MA 01778